(Q46876755)

26 December 2017

review article

1 reference

title

Escitalopram for treatment of major depressive disorder in adults (English)

1 reference

26 December 2017

major depressive disorder

1 reference

1 reference

1 reference

P M Llorca

1

1 reference

26 December 2017

G Brousse

series ordinal

2

1 reference

26 December 2017

R Schwan

series ordinal

3

1 reference

26 December 2017

publication date

1 July 2005

1 reference

26 December 2017

number of pages

12

1 reference

L'Encephale: revue de psychiatrie clinique biologique et therapeutique

inferred from page(s)

published in

1 reference

26 December 2017

volume

31

1 reference

26 December 2017

issue

4 Pt 1

1 reference

26 December 2017

page(s)

490-501

1 reference

26 December 2017

Antidepressant use patterns in clinical practices: comparisons among tricyclic antidepressants and selective serotonin reuptake inhibitors.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982410-8

Selective serotonin reuptake inhibitors in the treatment of affective disorders--III. Tolerability, safety and pharmacoeconomics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982410-8

The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982410-8

Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982410-8

Efficacy of escitalopram in patients with severe depression: a pooled analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982410-8

Efficacy of fluvoxamine in severe depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982410-8

A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982410-8

Third-generation antidepressants: do they offer advantages over the SSRIs?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982410-8

Escitalopram and suicidality in adult depression and anxiety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982410-8

Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982410-8

Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982410-8

The functioning and well-being of depressed patients. Results from the Medical Outcomes Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982410-8

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982410-8

7 January 2021

inferred from DOI database lookup

Antidepressants in long-term therapy: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982410-8

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1016/S0013-7006(05)82410-8

1 reference

26 December 2017

release_nvk2vojrmzgvxax4lghymh3bry

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nvk2vojrmzgvxax4lghymh3bry

24 November 2022

mapped directly with Wikidata item

1 reference

26 December 2017